News Releases Keyword Search Year None20232022202120202019201820172016 Nov-11-2020 Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2020 Virtual Annual Meeting Nov-09-2020 Oncternal Therapeutics to Present at Stifel Virtual Healthcare Conference Nov-04-2020 Oncternal Announces Third Quarter 2020 Financial Results and Provides Business Update Oct-06-2020 Oncternal Therapeutics Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TK216 for Treatment of Ewing Sarcoma Sep-21-2020 Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at ESMO Virtual Congress 2020 Sep-10-2020 Oncternal Therapeutics to Participate in September Investor Conferences Aug-27-2020 Oncternal Therapeutics Increases Previously Announced Bought Deal to $4.5 Million Aug-27-2020 Oncternal Therapeutics Announces $3.5 Million Bought Deal Offering Aug-06-2020 Oncternal Provides Business Update and Announces Second Quarter 2020 Financial Results Jul-30-2020 Oncternal Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last »